A study published in the British Journal of Cancer found that analyzing small extracellular vesicles (sEVs) could be useful in monitoring diffuse large B cell lymphoma (DLBCL).
In this study, GCB (SUDHL4 and SUDHL6), and ABC (OCI-LY3, OCI-LY10, and U2932) cell lines were used. sEVs were characterized using nanoparticle tracking analysis technology and western blot. CD20 content was also analyzed using enzyme-linked immunoassay, while the in vivo role of sEVs was evaluated in a xenograft model.
The results showed that sEVs production varied significantly between DLBCL cells, independent of subtype. CD20 level was found to be consistent with that of parental cells, determined in vitro and in vivo protection from rituximab, which seemed CD20 level-dependent; the protection was enhanced when sEVs were produced by 7,8-DHF-treated cells.
“DLBCL-derived sEVs have the differential capacity to interfere with immunotherapy, which could be enhanced by growth factors like neurotrophins,” the researchers concluded. “Evaluating the sEV CD20 level could be useful for disease monitoring.”
